米力农对新生儿持续肺动脉高压的治疗作用评价

Evaluation of the Therapeutic Effect of Milrinone on Continuous Pulmonary Hypertension in Neonates

目的探讨米力农治疗新生儿持续肺动脉高压的临床效果。方法选取本院于2015年12月-2018年12月收治的88例新生儿持续肺动脉高压患儿,随机分成试验组和参考组,每组各44例,参考组实行机械通气及对症治疗的常规方法,试验组在参考组基础上联合使用米力农治疗,比较两组患者的肺动脉平均压(PAMP)、肺动脉压(PAP)、血氧饱和度(SpO2)、动脉血氧分压(PaO2)等各项指标以及临床治疗总有效率及不良反应发生情况。结果试验组PAMP、PAP、SpO2、PaO2等各项指标均优于参考组(P <0.05),试验组的治疗总有效率高于参考组(P <0.05),试验组和参考组均有明显的不良反应。结论米力农治疗新生儿持续肺动脉高压的临床价值显著,能有效提高患儿的治疗总有效率,将患儿持续肺动脉高压状态控制下来。

Objective To investigate the clinical effect of milrinone in the treatment of neonatal persistent pulmonary hypertension. Methods Eighty-eight children with persistent pulmonary hypertension who were admitted to our hospital from December 2015 to December 2018 were randomly divided into experimental group and reference group, each with 44 cases. The reference group was treated with mechanical ventilation and symptomatic treatment. In the conventional method, the experimental group was combined with milrinone on the basis of the reference group, and the mean pulmonary artery pressure(PAMP), pulmonary arterial pressure(PAP), blood oxygen saturation(SpO2), and arterial oxygen partial pressure(PaO2) were compared between the two groups. And other indicators and the total effective rate of clinical treatment and adverse reactions. Results The indexes of PAMP, PAP, SpO2 and PaO2 in the experimental group were better than the reference group(P < 0.05). The total effective rate of the experimental group was higher than that of the reference group(P < 0.05). Both the experimental group and the reference group had Significant adverse reactions. Conclusion The clinical value of milrinone in the treatment of neonatal persistent pulmonary hypertension is significant, which can effectively improve the total effective rate of treatment in children, and control the sustained pulmonary hypertension in children.